



Cite this: *RSC Chem. Biol.*, 2021,
2, 166

Received 21st October 2020,
Accepted 30th November 2020

DOI: 10.1039/d0cb00190b

rsc.li/rsc-chembio

Biosynthesis of alkyne-containing natural products

Xinyang Li,^a Jian-Ming Lv,^b Dan Hu^{id}^b and Ikuro Abe^{id}^{*ac}

Alkyne-containing natural products are important molecules that are widely distributed in microbes and plants. Inspired by the advantages of acetylenic products used in the fields of medicinal chemistry, organic synthesis and material science, great efforts have focused on discovering the biosynthetic enzymes and pathways for alkyne formation. Here, we summarize the biosyntheses of alkyne-containing natural products and introduce *de novo* biosynthetic strategies for alkyne-tagged compound production.

1. Introduction

The alkyne is an important chemical functional moiety found in numerous natural products widely distributed in terrestrial bacteria, fungi, insects, and plants.¹ Marine organisms, such as microbes, algae and sponges also represent rich sources for producing acetylenic natural products.¹ Many of them display promising biological activities, such as anti-tumor, anti-parasitic, anti-malarial, and anti-HIV activities.¹ In

addition, the alkyne moiety is a valuable synthetic building block in organic chemistry. Conjugated enynes, including the 1,3-enyne motif and its derivatives found in many bioactive molecules,^{2,3} are important intermediates in the syntheses of organic compounds and macromolecules.^{4–7} The terminal alkyne is particularly useful for the alkyne–azide cycloaddition (“click” reaction), which enables the installation of a covalent bond of two chemical fragments to form complex molecular scaffolds for applications in pharmaceutical, cell biology and material sciences research.^{8–10} The alkyne can be used as an important bio-orthogonal tag and chemically or metabolically installed into biologically and medicinally important molecules, such as proteins, lipids, nucleic acids, and glycans.¹¹ This handle will enable the visualization and quantification of the alkyne-tagged molecules through bio-orthogonal chemistry. Additionally, the modes of action

^a Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: abei@mol.f.u-tokyo.ac.jp

^b Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China

^c Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo 113-8657, Japan



Xinyang Li

Xinyang Li received the BSc degree (2012) from Shaanxi University of Chinese Medicine and MSc degree (2015) from Nanjing University of Chinese Medicine. In 2019, she received her PhD degree in natural product chemistry from Zhejiang University. Then, she joined in Prof. Ikuro Abe's group in the University of Tokyo as a postdoctoral research fellow. Her research interest is the isolation and biosynthetic study of fungi-derived natural products.



Jian-Ming Lv

Jian-Ming Lv received his BS degree (2007) from Tianjin University and Master's degree (2010) from Zhejiang University. In 2014, he joined Prof. Xin-Sheng Yao's group at the College of Pharmacy, Jinan University, and earned his PhD degree (2017) in Medicinal Chemistry. Afterwards, he worked as a postdoctoral fellow at the College of Pharmacy, Jinan University, with Prof. Hao Gao and Prof. Dan Hu. His research interest is the isolation and biosynthetic study of fungi-derived natural products.



and cellular dynamics of these alkyne-tagged molecules can be investigated through click chemistry or directly by stimulated Raman scattering microscopy.^{12,13}

Given the importance of alkynes in both chemistry and biology, chemical synthesis and precursor directed biosynthesis have been used for alkyne-tagged compound production.^{14–17} Although total and semi-synthesis are powerful tools for chemical production, they are often restricted by the yield of target compounds and the availability of starting materials. For the precursor directed biosynthesis, a set of structural analogues can be obtained by feeding precursor variants to an organism; however, it is often challenging to incorporate the desired precursors into the biosynthetic pathway due to the substrate specificity of the enzymatic machinery. In addition, both the shunt transformation pathway and co-existence of precursors and target compounds pose challenges to selectively probe the target compounds in the system, thus impeding broader applications.¹⁸ Alternatively, *de novo* biosynthesis is another promising strategy for producing alkyne-tagged compounds, without feeding alkynic precursors. For this purpose, the biosynthesis of alkyne formation should be thoroughly understood. The discovery of the biosynthetic machineries for alkyne moieties has facilitated some illuminating progress in recent years. Hitherto, only a few types of genes have been identified as being involved in alkyne biosynthesis. Especially, the discovery of fatty acid/acyl acetylenases, a unique group of desaturases that catalyze alkyne formation in acetylenic fatty acids, is regarded as the first well studied example of the alkyne-forming enzymatic machinery.^{19,20} Furthermore, studies on the discovery of enzymes that catalyze alkyne formation in β -ethynylserine and alkynylated meroterpenoids have expanded the enzyme inventory and offered a potential route for the engineered biosynthesis of alkyne-tagged compounds.^{21–23} These findings have increased our understanding of the enzymatic machineries participating in

acetylenic natural product generation. Previously, Minto *et al.*²⁴ and Haritos *et al.*²⁵ summarized the biosynthesis of polyacetylenes and allied natural products. Herein, we update the recent research progress in the biosynthesis of alkyne-containing natural products and introduce *de novo* biosynthesis for *in situ* generating alkyne-tagged natural products.

2. Biosynthesis of acetylenic natural products

2.1 Fatty acids

Acetylenic fatty acids containing one or more C–C triple bonds are widespread metabolites in plants, fungi, marine sponges, and insects.^{26–28} Crepenynic acid (1), stearolic acid (2), and tariric acid (3) are general precursors to many acetylenic fatty acid-derived metabolites (Fig. 1A).^{29,30} Biosynthetic studies of crepenynic acid from *Crepis alpina* seed oil led to the characterization of the bifunctional enzyme Crep1, responsible for the double bond and subsequent acetylenic bond formation.³¹ The microsomal fraction from developing *C. alpina* seeds converted [¹⁴C]linoleic acid into [¹⁴C]crepenynic acid in the presence of NADH, clearly establishing that the Δ 12 triple bond formation employs an acyl chain with a double bond at Δ 12 position as a precursor (Fig. 1B). Furthermore, the *in vivo* heterologous expression of the *crep1* gene in *Saccharomyces cerevisiae* (YN94-1 strain) afforded results consistent with those from the *in vitro* experiment. The results reflected the recognition of a special fatty acid desaturase (FAD), designated as an acetylenase, which is capable of catalyzing the conversion of olefinic bonds to acetylenic bonds and is distinct from enzymes that only convert single bonds to double bonds.^{28,31,32}

Although the exact triple bond-forming mechanism by the acetylenase remains unclear due to the lack of a membrane desaturase crystal structure, the desaturase-mediated



Dan Hu

Dr Dan Hu received his PhD in 2010 in Integrated Biosciences from the University of Tokyo, Japan. He then did his post-doctoral research at the National Institute of Advanced Industrial Science and Technology (AIST). In 2013, he moved back to China and joined the college of pharmacy at Jinan University. In 2018, He was promoted to professor. His research interest has been focused on biosynthesis of fungi-derived biologically important natural products.



Ikuro Abe

Ikuro Abe received his BS (1984) and PhD (1989) from The University of Tokyo. After post-doctoral research with Professor Guy Ourisson, and mostly with Professor Michel Rohmer at the Ecole Nationale Supérieure de Chimie de Mulhouse (1989–1991), he worked with Professor Glenn D. Prestwich at the State University of New York at Stony Brook (1991–1996) and then at the University of Utah (1996–1998). In 1998, he moved back to Japan at the University of Shizuoka (1998–2009), and then was appointed as Professor of Natural Products Chemistry at the Graduate School of Pharmaceutical Sciences, The University of Tokyo (2009–current). His research interests mostly focus on exploring and engineering natural product biosynthesis.






Fig. 1 (A) Structures of 1–3. (B) Reactions catalyzed by the bifunctional Crep1.

formation of a double bond in a fatty acid is reportedly diiron-dependent,^{33–36} thus providing an important reference for understanding the triple C–C bond-forming reaction catalyzed by Crep1. Crep1 is composed of 375 amino acid residues and shares high sequence similarity to a widely distributed group of membrane-bound, non-heme diiron enzymes in living organisms.³⁵ As shown in Fig. 2, the selected sequences include mouse stearoyl-CoA desaturases 1 and 3, and other fatty acid desaturases from mammals, yeast, *Arabidopsis thaliana*, etc. Among them, the crystal structure of mouse stearoyl-CoA desaturase 1 (SCD1) (protein data bank ID 4YMK), an integral membrane protein, clearly shows the dizinc-center with longer

distance between the two metals which is different from previously solved structures of soluble di-iron enzymes.^{33,37} The other obvious difference is the absence of glutamate residue in the reported soluble enzymes.³³ As Zn²⁺ has an ionic radius of 0.88 Å, it may serve as a reasonable substitute for Fe²⁺ (0.92 Å) and didn't alter the structure of SCD1.³³ From the sequence alignment results (Fig. 2), the histidine motifs for di-iron center ligation in SCD1 are consistent with the reported desaturases. In addition to the two HxxHH and HxxxH motifs (marked in red frames) that are also conserved in Crep1, there are two other potential histidine-rich motifs (HHTH and HVMHH,

	1	10	20	30	40	50	60	70	80	90	100				
M. musculus (1)	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	GIFYYS	MTSAL	LGITAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
M. musculus (3)	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
H. sapiens	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
D. rerio	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
C. hyperboreus	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
C. elegans	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
S. cerevisiae	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
S. sp. PCC6803	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
A. thaliana	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
C. alpina	WRNIIIMVLLHLLGGLYG	ITLVPSCKLYTCLF	AFVYYS	VISAL	EGIGAG	HRLWSHRTYKARLP	LRIFLI	IANTMAF	QNDVYDWAR	HRHHKFSETHADPHNSR					
	110	120	130	140	150	160	170	180							
M. musculus (1)	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
M. musculus (3)	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
H. sapiens	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
D. rerio	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
C. hyperboreus	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
C. elegans	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
S. cerevisiae	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
S. sp. PCC6803	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
A. thaliana	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
C. alpina	RGFFFSHVGWLLVRKHP	AVKEKGGKLDMSD	KAEKLV	MFQR	RYKPG	LLLM	FILPTLV	PWYCW	CE	TFVNSL	LFVSTFLRY				
	190	200	210	220	230	240	250	260	270						
M. musculus (1)	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
M. musculus (3)	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
H. sapiens	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
D. rerio	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
C. hyperboreus	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
C. elegans	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
S. cerevisiae	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
S. sp. PCC6803	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
A. thaliana	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT
C. alpina	TVVNLATWLVNSAA	LYGYR	PDYKNI	QSR	ENILVSL	GAVGEG	FPH	YHHTFFPDY	SASEYR	WHINF	TFPFD	CDMAALGLAYD	DKKVS	SKATV	LARTKRT

Fig. 2 Partial sequence alignment of Crep1 with other integral membrane desaturases [The accession numbers for sequences included in the alignment are: mouse SCD1 (GI: 31543675), mouse SCD3 (GI: 13277368), human SCD1 (GI: 53759151), zebrafish SCD1 (GI: 28394115), *D. melanogaster* desat2 (GI: 24646295), *C. hyperboreus* ChDes9-1 (GI: 589834955), *C. elegans* FAT5 (GI: 544604099), delta-9 desaturase from *Synechocystis* sp. PCC 6803 (GI: 339274799), delta-9 desaturase from *A. thaliana* (GI: 18402641), yeast OLE1 (GI: 1322552), and Crep1 from *C. alpina* (Genbank accession No. CAA76158.2)]. (This alignment was generated by ESPrnt 3.0.⁴⁰)






Fig. 3 Proposed mechanism of non-heme diiron fatty acid desaturases that catalyze the oxidation from alkene to alkyne.

shadowed in red), indicating that Crep1 possesses a similar manner of metal chelation.

SCD1 catalyzes the C9–C10 *cis*-double bond formation from steryl-CoA to oleyl-CoA.³³ This step requires oxygen, which is activated by the metal center. The electrons needed for the desaturation reaction are obtained from cytochrome *b*₅, which in turn gained electrons from NAD(P)H *via* cytochrome *b*₅ reductase.³³ Fatty acid desaturation in plants also relies on cytochrome *b*₅ reductase to transfer electrons.³⁸ Crep1 may undergo two rounds of oxidation to catalyze the triple-bond formation in a saturated fatty acid. The kinetic isotope effect (KIE) study, using Crep1 expressed in yeast, supported a conventional two-step mechanism from alkene to alkyne.³⁹ The large primary deuterium isotope effect ($k_{\text{H}}/k_{\text{D}} = 14.6 \pm 3.0$) for C₁₂–H bond cleavage, and the minimal isotope effect of the C₁₃–H bond breaking step ($k_{\text{H}}/k_{\text{D}} = 1.25 \pm 0.08$), suggested that crepenynic acid is produced *via* an initial H-atom abstraction at C12 of a linoleoyl substrate (Fig. 3).³⁹

Intriguingly, a homolog of Crep1 has been discovered in the biosynthetic gene cluster of falcarindiol (5),⁴¹ a dietary metabolite from edible crops such as carrots, tomatoes and celery, that exhibits antifungal activity and cytotoxicity against several human cancer cell lines. The conversion of linoleic acid (4) to crepenynic acid (5) by a Crep1-like acetylenase was proposed to be involved in an early catalytic step in the falcarindiol biosynthetic pathway in tomato (*Solanum lycopersicum*) (Fig. 4).⁴¹ As only a few amino acid changes distinguish acetylenases from other desaturases, it is difficult to find orthologs of Crep1 by a

homology search of genome databases. Instead, researchers correlated the expression levels of 40 corresponding transcripts from their RNA sequencing datasets with the falcarindiol accumulation in tomato leaves, to prioritize the putative acetylenases responsible for falcarindiol alkyne installation. Four sequentially located genes, with expression levels showing the best correlations with falcarindiol accumulation, were predicted to encode a cluster of enzymes for falcarindiol alkyne formation. Two genes (*ACET1a* and *ACET1b*) from the candidate cluster were determined to possess acetylenase activity by analyses of their overexpression in the heterologous host *Nicotiana benthamiana*. The results revealed that *ACET1a* and *ACET1b* encode identical acetylenases that catalyze the conversion of linoleic acid to crepenynic acid in the first step of falcarindiol biosynthesis in tomato. In addition to *ACET1a* and *ACET1b*, *Solyc12g100250* and *Solyc12g100270*, which respectively encode a desaturase and a putative decarboxylase, are also involved in the biosynthesis of falcarindiol (Fig. 4).⁴¹

2.2 Polyketides

Many microbial and marine polyacetylenes are formed from polyketides or peptides. Eneidyne natural products, mainly produced by soil and marine microorganisms, have an unusual bicyclo[7.3.0]-dodecadienediynene core that contains the 1,5-diyne-3-ene unit embedded in a 9-membered ring or the bicyclo[7.3.1]-tridecadienyne core in a 10-membered ring.^{42,43} These kinds of natural products feature special molecular architectures with promising antibiotic and antitumor




Fig. 4 Proposed pathway from linoleic acid to falcarindiol.






Fig. 5 (A) Structures of **6–8**. (B) Postulated biosynthetic routes to 9- and 10-membered enediynes.

activities that are attracting considerable attention.^{44,45} The subunit six-carbon enediyne was investigated to determine whether it is the key structural element responsible for the biological activity. The enediyne moiety can form a reactive diradical intermediate by Bergman cyclisation. The highly reactive diradical abstracts hydrogen atoms from the DNA and generates a carbon-centered radical, leading to double stranded DNA cleavage in the presence of O₂.^{45,46}

Early experiments feeding 9-membered neocarzinostatin⁴⁷ and 10-membered esperamicin⁴⁸ with ¹³C-labeled sodium acetate to their producers revealed that each was formed by the head-to-tail assembly of acetate units. In 2002, Shen and co-workers identified the biosynthetic gene cluster of C-1027 (**6**), a chromoprotein antibiotic isolated from *Streptomyces globisporus*, by chromosomal walking from the *sgcAB* locus, which is essential for **6** production in *S. globisporus*.^{49,50} At the same time, Thorson and co-workers identified the biosynthetic gene locus for calicheamicin γ (**7**) by screening a genomic library for cosmids

that confer calicheamicin resistance to *Micromonospora echinospora*.⁵¹ Both gene clusters contain the five-gene cassette (the minimal enediyne PKS gene cassette or warhead gene cassette) proposed to be responsible for enediyne core formation (Fig. 5A). Genome mining of the gene clusters producing other enediyne natural products and sequencing of some microbial genomes in the following years further confirmed the conservation of the warhead gene cassettes.^{52–56}

Shen's group co-expressed the PKS (SgcE) for C-1027 with its cognate thioesterase TE (SgcE10) in *E. coli*, which produced a 15-carbon polyene (**9**).⁵⁷ Further *in vivo* experiments showed that SgcE can be incorporated into the biosynthetic pathways of other 9-membered enediynes, supporting the idea that **9** is the precursor to the 9-membered enediyne cores. Meanwhile, Liang and co-workers obtained a linear carbonyl-conjugated polyene (**11**), from the enzymatic assay of the PKS (CalE8) of **7** with the assistance of its TE (CalE7).^{58,59} Using mass spectrometry, Townsend and co-workers proposed that **11** was derived



from a β -keto carboxylic intermediate (**10**) (Fig. 5B).⁶⁰ The enediyne core and the other polyketide moieties of the enediyne-containing compounds were considered to have different biosynthetic origins.^{51,52} Interestingly, by gene deletion and ¹⁸O-labeling experiments, Townsend's group recently demonstrated that the enediyne PKS, DynE8, plays a dual role in the biosyntheses of the enediyne core and the anthraquinone scaffold in dynemicin A (**8**).^{61,62} Furthermore, Liang proposed that CalU15, encoded by a gene in the warhead gene cassette of 7 and sharing minimal sequence identity with the families of diiron containing desaturases or acetylenases, catalyzes the acetylenic bond formation in the 1,5-diyne-3-ene unit.⁵⁸ However, the enzymatic activity of the protein must still be proved.

2.3 Polyketide/non-ribosomal peptide hybrids

The first gene clusters for terminal alkyne biosynthesis were identified from jamaicamide B (**12**) and carmabin A (**13**), which are terminal alkyne-bearing polyketide–nonribosomal peptide (PK–NRP) hybrids produced by the marine cyanobacteria *Moorea producens* JHB and *M. producens* 3L, respectively.^{20,63} A bioinformatics analysis revealed the conserved trigene cassettes, *jamABC* and *camABC*, with high amino acid sequence identities of 95.7–97.4%.⁶⁴ JamA is a fatty acyl-CoA ligase, while JamB is a membrane associated fatty acid desaturase with strict substrate specificity for 5-hexanoic acid, and together with JamC, an acyl carrier protein (ACP), they are responsible for alkyne formation in a PKS–NRPS system.²⁰ In addition, genome mining revealed more than 80 gene operons homologous to *jamABC* across diverse bacterial genera, indicating that this

gene operon is likely to be employed in the synthesis of a variety of natural products containing an alkyne motif.¹⁹ Further experimental studies determined the biosynthetic pathway of the terminal alkyne generated by the three proteins. Hexanoic acid was first activated with ATP by JamA, and then loaded onto the ACP JamC. Subsequent dehydrogenation of the terminal alkene moiety was accomplished by the membrane associated fatty acid desaturase/acetylenase JamB to generate the terminal alkyne (Fig. 6B).^{65,66} Zhang's group further demonstrated that desaturase/acetylenase (JamB) has a more stringent interaction with ACP than the acyl-ACP ligase (JamA) by both *in vitro* and *in vivo* assays, which provided new insights into the role of ACP in alkyne biosynthesis.⁶⁷

The discovery of the first terminal alkyne biosynthetic pathway has inspired further characterizations and applications of this unique biosynthetic route. Genome mining of *JamABC* homologs led to the discovery of the new terminal alkyne biosynthetic cassette *ttuABC*, from *Teredinibacter turnerae* T7901.¹⁹ TtuABC shows an analogous mode of action with *JamABC* to form a terminal alkyne moiety. The medium-chain fatty acid is activated by acyl-CoA ligase TtuA and load onto carrier protein TtuC. One obvious difference between operons TtuABC and *JamABC* is that the desaturase/acetylenase TtuB is specific for decanoic acid (C₁₀ chain length) rather than hexanoic acid (C₆ chain length) for substrate selection (Fig. 6C).¹⁹

Gerwick and co-workers discovered vatiamides A–D (**14–17**) from *Moorea producens*, which feature a fatty acid tail harboring a terminal alkyne or bromoalkyne that is identical to the moiety found in jamaicamides.^{20,68} Genome mining of *jamABC*




Fig. 6 (A) Structures of **12** and **13**. (B) The biosynthetic pathway for the C₆ alkyne starter unit generation and incorporation into jamaicamide B. (C) Terminal alkyne biosynthetic pathways of *JamABC* and *TtuABC* that modify C₆ and C₁₀ fatty acids, respectively.






Fig. 7 (A) Structures of 14–19. (B) Biosynthetic pathway of vatiamides in *Moorea producens*.

homologs identified the PKS/NRPS gene cluster *vatA-O* responsible for the formation of vatiamides A and B. Efforts toward finding the genes for the biosynthesis of vatiamides C and D illuminated a 40 kb extension of NRPS and PKS modules downstream of *vatO* in the original 50 kb cluster. This research characterized the first example of a special combinatorial non-collinear PKS/NRPS system in which the upstream PKS cassette interacts with three separate NRPS partners (Fig. 7B). Terminal alkynes can undergo a copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction to allow sensitive alkyne identification in a crude extract.²⁸ The researchers synthesized a fluorogenic “click”-based probe that exhibited a potent fluorescence increase at 490 nm in the triazole adduct formation. Three alkynylated lipopeptides and their brominated analogues vatiamides A–F (14–19), which are predicted to be produced by the unique non-collinear PKS/NRPS system, were discovered with the use of this fluorogenic azide-based click probe (Fig. 7A).⁶⁸

2.4 Amino acids

A series of terminal alkyne-containing amino acids are reportedly produced by fungi and bacteria.^{69,70} Early studies revealed that some terminal alkynes originate from fatty acid or polyketide biosynthetic pathways.^{24,65} Recently, Chang and co-workers characterized a unique pathway to produce a terminal alkyne-containing amino acid, β -ethynylserine (β es) (20), from *Streptomyces cattleya*.²¹ Knock outs of three fatty acid desaturases (SCAT_4823, SCAT_p1525 and SCAT_0184) did not disrupt β es production, thus suggesting a different route than canonical desaturation for target compound production. The putative biosynthetic gene cluster (BesA-F), related to amino acid metabolism, was identified by a genomic comparison of two *Streptomyces* spp. that produce acetylenic amino acids (Fig. 8A) with 26 other control *Streptomyces* spp. genomes.²¹ In contrast to jamaicamide B, terminal alkyne installation in β es is catalyzed by three crucial enzymes, including BesB, a pyridoxal-5'-phosphate (PLP)-dependent cystathionine- β -lyase






Fig. 8 (A) Terminal-alkyne amino acids from *Streptomyces* spp. (B) Proposed biosynthetic pathway of βes from L-lysine. (C) Putative mechanism for BesB-catalyzed formation of Pra (**21**) from 4-Cl-allylglycine (**24**).

homolog, BesC, which shares homology with the non-heme iron oxidase HemeO superfamily, and BesD, a non-heme Fe/α-ketoglutarate (αKG)-dependent oxygenase.²¹ The pathway involves multiple unique functional groups to yield the terminal alkyne, including the BesD-mediated 4-chlorination of L-lysine (**23**), followed by oxidative cleavage *via* BesC to produce a chlorinated terminal alkene (**24**), with ammonia and formaldehyde

as co-products. BesB catalyzes the conversion of **24** to **21** with the aid of a PLP cofactor. To probe the mechanism of BesB, **24** was used as substrate in D₂O and led to the formation of [M + 2D]⁺ Pra which suggested at least two deprotonation–protonation events occurring during the BesB catalysis. The C_α-deprotonation giving the 4-Cl-Alg-ketimine intermediate is consistent with the cystathionine γ-synthase mechanism.⁷¹



Further deprotonation at the β position initiated the elimination of chloride to form an allene intermediate (27). The terminal alkyne was formed by subsequent isomerization of the allene intermediate and release from PLP (Fig. 8B and C). Pra is then ligated to glutamate to form the γ -glutamyl-L-dipeptide (25), which is the substrate of the BesE hydroxylase to produce the β es dipeptide (26). Notably, the glutamylation step is considered to be a physiological step that reduces side reactions and facilitates transport. The amide hydrolase is responsible for the release of free Pra (21) and β es (20).²¹

Searches for BesA-D homologs revealed five additional *Streptomyces* spp. with the genes encoding the proteins, but their abilities to produce terminal alkyne containing amino acids have not been reported.²¹ Subsequently, the authors found that three of the strains could produce either Pra or β es. Their discovery will lead to the identification of enzyme homologs responsible for the formation of a wider range of terminal alkyne amino acid products. In addition, characterization of the β es biosynthetic pathway will provide an opportunity for the production of non-proteinogenic amino acids, such as halo-, terminal-alkene and terminal-alkyne amino acids, that can be used for downstream applications.²¹

2.5 Meroterpenoids

Acetylenic meroterpenoids are structurally unique compounds with an alkynyl moiety in prenyl chains. These compounds display a wide range of properties, such as cytotoxic, antifungal and antibacterial bioactivities.^{72,73} Although some chemical approaches have been developed to synthesize these acetylenic compounds, little is known about the biosynthesis and molecular basis for the acetylenic prenyl chain formation.^{74,75}

Recently, two research groups simultaneously reported that the alkynyl moieties in the prenyl chains of biscognienyne B (28) and asperpentyn (29) are generated by cytochrome P450 enzymes, as determined *via* heterologous expression, feeding experiments and *in vitro* enzyme reactions.^{22,23} Furthermore, the two groups demonstrated that the stereochemistry of the double bond in the intermediates is important for substrate recognition.

Gao and co-workers previously isolated 28 and several other acetylenic meroterpenoids from an endolichenic fungus *Biscogniauxia* sp. (71-10-1-1).⁷⁶ Based on the previously reported prenyl-transferase IacE and the cupin protein IacF, which are reportedly associated with the biosynthesis of biscognienyne B,⁷⁷ they identified the putative gene cluster consisting of 11 genes. Through heterologous expression in *Aspergillus oryzae* NSAR1, feeding experiments and *in vitro* assays, they demonstrated that 28 is synthesized from 4-hydroxybenzoic acid (30) by six enzymes (Fig. 9A).²² Particularly, they found that the alkyne in 28 was installed by the cytochrome P450 enzyme BisI, which is different from the other reported enzymes dedicated to acetylenic bond biosynthesis. In order to explore the mechanism and substrate scope of the BisI-mediated biosynthesis of the alkynyl moiety, the authors chemically prepared the 1-OH methylated form (31) of 4-hydroxy-3-prenylbenzoic acid and performed feeding experiments (Fig. 9B). The results indicated that BisI can convert 31 to the dehydrogenated product (7E)-diene (32). However, further feeding experiments and *in vitro* assays revealed that BisI cannot accept 32 or its demethylated derivative 33 as a substrate to yield the corresponding acetylenic products, but it shows promiscuous activities towards C5 and C15 prenyl chains.²²

Meanwhile, Lin and co-workers identified the similar cytochrome P450 enzyme AtyI, responsible for the 1,3-enyne formation in



Fig. 9 (A) Proposed biosynthetic pathway for biscognienyne B. (B) The substrate scope of BisI.





Fig. 10 Proposed mechanisms of (A) AtyI-catalyzed synthetic substrate analogs **34** and **38** by feeding experiments, and (B) the natural AtyI-catalyzed pathway from **40** to asperpentin (**29**).

asperpentin (**29**) (Fig. 10B).²³ To investigate the mechanism of the enyne moiety formation by AtyI, a series of substrate derivatives were synthesized and fed to *Saccharomyces cerevisiae* expressing *atyI*. Feeding (7Z)-alkene (**34**) to *S. cerevisiae* expressing *atyI* led to the production of compound **35**, while (7E)-alkene (**37**) could not be converted (Fig. 10A). Further experiments feeding **35** and its 4-OH methylated derivative **36** to *S. cerevisiae* expressing *atyI* showed no conversion to the enyne, suggesting that 7-alkyne containing intermediates were not involved in the enyne formation by AtyI. In contrast, when

S. cerevisiae expressing *atyI* was fed **38**, compound **39** was detected (Fig. 10A). The above results indicated that the AtyI-catalyzed formation of the 1,3-enyne moiety occurs through a (7Z)-diene intermediate. This P450 monooxygenase was thus verified to possess dual functions. It catalyzes prenyl chain dehydrogenation to yield a (7Z)-diene from **40**, followed by further dehydrogenation to form the 1,3-enyne moiety (Fig. 10B).²³ The formation of the (7Z)-diene intermediate might be conducive to the abstraction of the two hydrogen atoms on the same side, by the active ferryl-oxo complex of the



P450 enzyme. Particularly, Compound I sequentially abstracts the 7-H and 8-H to give the enyne moiety. This mechanism is similar to that of a fatty acid desaturase; however, the iron cofactors are different. This hypothesis also suggests opportunities for discovering novel acetylenic meroterpenoids and expanding the enzymatic tools for the *de novo* biosynthesis of alkyne-tagged compounds.

3. Engineered biosynthesis of alkyne-tagged products

Tagging natural products with a unique chemical handle facilitates the stabilization, quantification, visualization, and functional analysis of natural products through bioorthogonal chemistry.^{78–80} In particular, the terminal alkyne can be widely employed through the Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC) ‘click’ reaction, which is one of the most powerful tools in chemical biology.^{68,81–83} In addition to tagging natural products by semi-synthesis¹⁴ and total synthesis,¹⁵ precursor-directed biosynthesis, which is a more facile and gentle way of chemical synthesis, has been used for azide- or

alkyne-tag installation.^{16,84,85} However, for precursor-directed biosynthesis, a major limitation is the low conversion efficiency of precursor into product, which in turn causes the problem of the coexistence of precursors and products with the same chemical handle.¹⁸ Given the progress achieved toward understanding alkyne biosynthesis, *de novo* biosynthesis, which is employed for the creation of alkyne-labeled molecules through biosynthetic pathway engineering, has drawn keen attention. This strategy avoids the feeding of alkynic precursors and overcomes the limitation of precursor-directed biosynthesis.⁶⁵

The function of the trigene cassette *jamABC* for terminal alkyne formation in jamaicamide B was first biochemically characterized by Zhang *et al.*⁶⁵ Based on this result, they generated a JamABC *in situ* system for introducing terminal alkyne tags into natural products. JamB has strict substrate specificity for 5-hexanoic acid and the acyl carrier protein (JamC, CamC). Therefore, only a 5-hexynoyl moiety is incorporated into alkyne-tagged natural products by the JamABC *in situ* system. The terminal alkyne biosynthetic cassette was first co-expressed with a type III PKS (HsPKS1) system in a starter unit, with malonyl-CoA as the extension unit, in the *E. coli* BAP1 strain. After induction by IPTG, the strain was grown for 2 days



Fig. 11 (A) Biosynthesis of **41** via starter unit engineering. (B) Biosynthesis of **42** via extender unit engineering.






Fig. 12 (A) Biosynthesis of **43** using the *in vivo* TtuABC system. (B) Scheme of the *in vivo* (or *in vitro*) reactions between JamABC and engineering type I PKSs, LipPKS1* and DEBSM6*, to produce **44**.

in F1 minimal medium supplemented with 5-hexanoic acid. Analysis of the culture extracts revealed the production of the terminal alkyne-tagged PK compound **41** (compound **3** in ref. 65) (Fig. 11A). However, the low activity of JamB leads outcompeted 5-hexenoic acid supplied than the target terminal alkyne. Zhang and co-workers improved the activity of JamB up to 20-fold to convert hexanoic acid to the terminal alkyne in *E. coli* and developed a rapid and sensitive platform through fluorogenic click reaction for detecting extracellular alkyne-tagged metabolites directly in crude cultures.⁸⁶

Further explorations for incorporating an alkyne extender unit into the molecular scaffolds of PKs employed the gene cassette *antCDEFGM*, required for the generation of the antimycin dilactone scaffold,⁸⁷ and the *jamABC* cassette. Liu and co-workers demonstrated that an alkyne extender unit can be accepted by the promiscuous AntE (crotonyl-CoA reductase/coxylase (CCR)-like protein) and the acyltransferase (AT) domain embedded in AntD to synthesize an alkyne-labeled antimycin by the precursor directed biosynthesis in *Streptomyces*.⁸⁸ To avoid feeding alkyne precursors, co-expression of the two gene cassettes, *antCDEFGM* and *jamABC*, in *E. coli* BAP1 led to the production of the alkyne-bearing PK/NRP hybrid antimycin analog **42** (compound **5** in ref. 65) (Fig. 11B).⁶⁵

TtuABC, encoded from the genome of *T. turnerae* T7901, shows a similar mode of function to JamABC in forming a terminal alkyne moiety. TtuABC has different substrate specificity towards fatty acyl moieties with a C₁₀ chain length, instead of hexanoic acid (C₆ chain length). Zhang's group employed the type III PKS (HsPKS1) in a TtuABC *in situ* system that specifically recognized the C₁₀ fatty acid of the starter unit to generate the novel terminal alkyne-tagged polyketide compound **43** (compound **1** in ref. 19) in *E. coli* (Fig. 12A).¹⁹

Based on these results, they proved that PKS starter unit engineering is a viable way to install the alkyne moiety from JamABC onto a polyketide to generate terminal alkyne-tagged products. They further tried to generalize this strategy to other kinds of PKSs by employing two well studied type I PKSs, LipPKS1 and DEBSM6, to produce the target alkyne-tagged polyketides.⁸⁹ LipPKS1 is the first module in lipomycin biosynthesis and DEBSM6 is the last PKS module in the erythromycin biosynthetic pathway.^{90,91} Engineered LipPKS1 and DEBSM6 have been constructed to utilize malonyl-CoA instead of methylmalonyl-CoA as the extender unit, with the promiscuous DEBS thioesterase, to promote the release of a carboxylic acid product.⁹² Zhang and co-workers further removed the AT and ACP loading domains of the engineered LipPKS1, to create a truncated version that facilitates the alternative starter unit incorporation. The two engineered modules (LipPKS1* and DEBSM6*), in combination with JamABC working as a *trans* loading system, were employed to produce the alkyne-tagged polyketide 3-hydroxydec-9-ynoic acid (**44**) (compound **1** in ref. 89) (Fig. 12B).⁸⁹ These findings have shed light on the discovery and development of synthetic tools for the *de novo* biosynthesis of various acetylenic products.

4. Conclusion

The alkyne is a biological and chemical functional moiety found in numerous natural products. Hitherto, a few types of gene cassettes were identified in the biosynthetic pathways of alkyne-containing natural products. The recent progress in identifying the biosynthetic enzymes and pathways of acetylenic products offers a potential route for the *de novo*



biosynthesis of alkyne-labeled products, for use as powerful tools for diverse downstream applications in drug discovery and chemical biology. Meanwhile, with these enzymes in hand, finding more homologs will lead to an expanded alkyne biosynthetic enzyme inventory capable of efficiently generating acetylenic products.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors would like to express sincere appreciation to an excellent group of coworkers whose contributions are cited in the text. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (JSPS KAKENHI Grant No. JP16H06443, JP20H00490, and JP20KK013), and Japan Science and Technology Agency (JST SICORP Grant No. JPMJSC1701).

References

- Q. Y. Chai, Z. Yang, H. W. Lin and B. N. Han, *Mar. Drugs*, 2016, **14**, 216.
- K. C. Nicolaou, W. M. Dai, S. C. Tsay, V. A. Estevez and W. Wrasidlo, *Science*, 1992, **256**, 1172–1178.
- H. Kim, H. Lee, D. Lee, S. Kim and D. Kim, *J. Am. Chem. Soc.*, 2007, **129**, 2269–2274.
- P. Wessig and G. Müller, *Chem. Rev.*, 2008, **108**, 2051–2063.
- K. Campbell, C. J. Kuehl, M. J. Ferguson, P. J. Stang and R. R. Tykwinski, *J. Am. Chem. Soc.*, 2002, **124**, 7266–7267.
- G. Chen, L. Wang, D. W. Thompson and Y. Zhao, *Org. Lett.*, 2008, **10**, 657–660.
- B. M. Trost and J. T. Masters, *Chem. Soc. Rev.*, 2016, **45**, 2212–2238.
- Y. Jiang, J. Chen, C. Deng, E. J. Suuronen and Z. Zhong, *Biomaterials*, 2014, **35**, 4969–4985.
- C. G. Liu, Y. Wang, P. Liu, Q. L. Yao, Y. Y. Zhou, C. F. Li, Q. Zhao, G. H. Liu and X. L. Zhang, *ACS Chem. Biol.*, 2020, **15**, 1554–1565.
- Z. Hao, S. Hong, X. Chen and P. R. Chen, *Acc. Chem. Res.*, 2011, **44**, 742–751.
- M. Grammel and H. C. Hang, *Nat. Chem. Biol.*, 2013, **9**, 475–484.
- P. Thirumurugan, D. Matosiuk and K. Jozwiak, *Chem. Rev.*, 2013, **10**, 4905–4979.
- L. Wei, F. Hu, Y. Shen, Z. Chen, Y. Yu, C. C. Lin, M. C. Wang and W. Min, *Nat. Methods*, 2014, **11**, 410–412.
- J. Seidel, Y. Miao, W. Porterfield, W. Cai, X. Zhu, S. J. Kim, F. Hu, S. Bhattarai-Kline, W. Min and W. Zhang, *Chem. Commun.*, 2019, **55**, 9379–9382.
- I. Staub and S. A. Sieber, *J. Am. Chem. Soc.*, 2008, **130**, 13400–13409.
- C. J. Harvey, J. D. Puglisi, V. S. Pande, D. E. Cane and C. Khosla, *J. Am. Chem. Soc.*, 2012, **134**, 12259–12265.
- K. Bravo-Rodriguez, S. Klopries, K. R. M. Koopmans, U. Sundermann, S. Yahiaoui, J. Arens, S. Kushnir, F. Schulz and E. Sanchez-Garcia, *Chem. Biol.*, 2015, **19**, 1425–1430.
- J. F. Martin, J. Casqueiro and P. Liras, *Curr. Opin. Microbiol.*, 2005, **8**, 282–293.
- X. Zhu, M. Su, K. Manickam and W. Zhang, *ACS Chem. Biol.*, 2015, **10**, 2785–2793.
- D. J. Edwards, B. L. Marquez, L. M. Nogle, K. McPhail, D. E. Goeger, M. A. Roberts and W. H. Gerwick, *Chem. Biol.*, 2004, **11**, 817–833.
- J. A. Marchand, M. E. Neugebauer, M. C. Ing, C. I. Lin, J. G. Pelton and M. C. Y. Chang, *Nature*, 2019, **567**, 420–424.
- J. M. Lv, Y. H. Gao, H. Zhao, T. Awakawa, L. Liu, G. D. Chen, X. S. Yao, D. Hu, I. Abe and H. Gao, *Angew. Chem., Int. Ed.*, 2020, **132**, 13633–13638.
- Y. R. Chen, A. Naresh, S. Y. Liang, C. H. Lin, R. J. Chein and H. C. Lin, *Angew. Chem., Int. Ed.*, 2020, **59**, 13537–13541.
- R. E. Minto and B. J. Blacklock, *Prog. Lipid Res.*, 2008, **47**, 233–306.
- V. S. Haritos, *Nat. Chem. Biol.*, 2015, **11**, 98–99.
- B. J. Blacklock, B. E. Scheffler, M. R. Shepard, N. Jayasuriya and R. E. Minto, *J. Biol. Chem.*, 2010, **285**, 28442–28449.
- V. S. Haritos, I. Horne, K. Damcevski, K. Glover, N. Gibb, S. Okada and M. Hamberg, *Nat. Commun.*, 2012, **3**, 1150.
- C. Ross, K. Scherlach, F. Kloss and C. Hertweck, *Angew. Chem., Int. Ed.*, 2014, **53**, 7794–7798.
- X. Bao, S. Katz, M. Pollard and J. Ohlrogge, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 7172–7177.
- N. El-Jaber, A. Estevez-Braun, A. G. Ravelo, O. Munoz-Munoz, A. Rodriguez-Afonso and J. R. Murguia, *J. Nat. Prod.*, 2003, **66**, 722–724.
- M. Lee, M. Lenman, A. Banaś, M. Bafor, S. Singh, M. Schweizer, R. Nilsson, C. Liljenberg, A. Dahlqvist, P.-O. Gummeson, S. Sjödal, A. Green and S. Stymne, *Science*, 1998, **280**, 915–918.
- J. Shanklin, J. E. Guy, G. Mishra and Y. Lindqvist, *J. Biol. Chem.*, 2009, **284**, 18559–18563.
- Y. Bai, J. G. McCoy, E. J. Levin, P. Sobrado, K. R. Rajashankar, B. G. Fox and M. Zhou, *Nature*, 2015, **524**, 252–256.
- H. G. Enoch, A. Catalá and P. Strittmatter, *J. Biol. Chem.*, 1976, **251**, 5095–5103.
- J. Shanklin, E. Whittle and B. G. Fox, *Biochemistry*, 1994, **33**, 12787–12794.
- P. H. Buist and B. Behrouzian, *Prostaglandins, Leukotrienes Essent. Fatty Acids*, 2003, **68**, 107–112.
- M. Högbom, Y. Huque, B.-M. Sjöberg and P. Nordlund, *Biochemistry*, 2002, **41**, 1381–1389.
- L. L. Wayne, J. G. Wallis, R. Kumar, J. E. Markham and J. Browse, *Plant Cell*, 2013, **25**, 3052–3066.
- D. W. Reed, D. R. Polichuk, P. H. Buist, S. J. Ambrose, R. J. Sasata, C. K. Savile and P. S. Covello, *J. Am. Chem. Soc.*, 2003, **125**, 10635–10640.
- X. Robert and P. Gouet, *Nucleic Acids Res.*, 2014, **42**, W320–W324.



- 41 J. E. Jeon, J. G. Kim, C. R. Fischer, N. Mehta, C. Dufour-Schroif, K. Wemmer, M. B. Mudgett and E. Sattely, *Cell*, 2020, **180**, 176–187.e19.
- 42 K. Edo, M. Mizugaki, Y. Koide, H. Seto, K. Furihata, N. Ōtake and N. Ishida, *Tetrahedron Lett.*, 1985, **26**, 331–334.
- 43 M. D. Lee, T. S. Dunne, C. C. Chang, G. A. Ellestad, M. M. Siegel, G. O. Morton and D. B. Borders, *J. Am. Chem. Soc.*, 1987, **109**, 3466–3468.
- 44 J. Thorson, E. Sievers, J. Ahlert, E. Shepard, R. Whitwam, K. Onwueme and M. Ruppen, *Curr. Pharm. Des.*, 2000, **6**, 1841–1879.
- 45 A. L. Smith and K. C. Nicolaou, *J. Med. Chem.*, 1996, **39**, 2103–2117.
- 46 J. B. Biggins, J. R. Prudent, D. J. Marshall, M. Ruppen and J. S. Thorson, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 13537–13542.
- 47 O. D. Ssensens, J. L. Giner and I. H. Goldberg, *J. Am. Chem. Soc.*, 1989, **111**, 3295–3299.
- 48 K. S. Lam, J. A. Veitch, J. Golik, B. Krishnan, S. E. Klohr, K. J. Volk, S. Forenza and T. W. Doyle, *J. Am. Chem. Soc.*, 1993, **115**, 12340–12345.
- 49 W. Liu and B. Shen, *Antimicrob. Agents Chemother.*, 2000, **44**, 382–392.
- 50 W. Liu, S. D. Christenson, S. Standage and B. Shen, *Science*, 2002, **297**, 1170–1173.
- 51 J. Ahlert, E. Shepard, N. Lomovskaya, E. Zazopoulos, A. Staffa, B. O. Bachmann, K. Huang, L. Fonstein, A. Czisny, R. E. Whitwam, C. M. Farnet and J. S. Thorson, *Science*, 2002, **297**, 1173–1176.
- 52 W. Liu, K. Nonaka, L. P. Nie, J. Zhang, S. D. Christenson, J. Bae, S. G. Van Lanen, E. Zazopoulos, C. M. Farnet, C. F. Yang and B. Shen, *Chem. Biol.*, 2005, **12**, 293–302.
- 53 Q. Gao and J. S. Thorson, *FEMS Microbiol. Lett.*, 2008, **282**, 105–114.
- 54 S. G. Van Lanen, T. J. Oh, W. Liu, E. Wendt-Pienkowski and B. Shen, *J. Am. Chem. Soc.*, 2007, **129**, 13082–13094.
- 55 D. W. Udway, L. Zeigler, R. N. Asolkar, V. Singan, A. Lapidus, W. Fenical, P. R. Jensen and B. S. Moore, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 10376–10381.
- 56 Z. J. Low, G. L. Ma, H. T. Tran, Y. Zou, J. Xiong, L. Pang, S. Nuryyeva, H. Ye, J. F. Hu, K. N. Houk and Z. X. Liang, *J. Am. Chem. Soc.*, 2020, **142**, 1673–1679.
- 57 J. Zhang, S. G. V. Lanen, J. Ju, W. Liu, P. C. Dorrestein, W. Li, N. L. Kelleher and B. Shen, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 1461–1465.
- 58 R. Kong, L. P. Goh, C. W. Liew, Q. S. Ho, E. Murugan, B. Li and Z. X. Liang, *J. Am. Chem. Soc.*, 2008, **130**, 8142–8143.
- 59 M. Kotada, R. Kong, I. Qureshi, Q. S. Ho, H. Sun, C. W. Liew, L. P. Goh, P. Cheung, Y. Mu, J. Lescar and Z. X. Liang, *J. Biol. Chem.*, 2009, **284**, 15739–15749.
- 60 K. Belecki, J. M. Crawford and C. A. Townsend, *J. Am. Chem. Soc.*, 2009, **131**, 12564–12566.
- 61 D. R. Cohen and C. A. Townsend, *Nat. Chem.*, 2018, **10**, 231–236.
- 62 D. R. Cohen and C. A. Townsend, *Angew. Chem., Int. Ed.*, 2018, **57**, 5650–5654.
- 63 K. L. McPhail, J. Correa, R. G. Linington, J. González, E. Ortega-Barría, T. L. Capson and W. H. Gerwick, *J. Nat. Prod.*, 2007, **70**, 984–988.
- 64 A. C. Jones, E. A. Monroe, S. Podell, W. R. Hess, S. Klages, E. Esquenazi, S. Niessen, H. Hoover, M. Rothmann, R. S. Lasken, J. R. Yates III, R. Reinhardt, M. Kube, M. D. Burkart, E. E. Allen, P. C. Dorrestein, W. H. Gerwick and L. Gerwick, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 8815–8820.
- 65 X. Zhu, J. Liu and W. Zhang, *Nat. Chem. Biol.*, 2015, **11**, 115–120.
- 66 P. C. Dorrestein, J. Blackhall, P. D. Straight, M. A. Fischbach, S. Garneau-Tsodikova, D. J. Edwards, S. McLaughlin, M. Lin, W. H. Gerwick, R. Kolter, C. T. Walsh and N. L. Kelleher, *Biochemistry*, 2006, **45**, 1537–1546.
- 67 M. Su, X. Zhu and W. Zhang, *AIChE J.*, 2018, **64**, 4255–4262.
- 68 N. A. Moss, G. Seiler, T. F. Leao, G. Castro-Falcon, L. Gerwick, C. C. Hughes and W. H. Gerwick, *Angew. Chem., Int. Ed.*, 2019, **58**, 9027–9031.
- 69 M. Sanada, T. Miyano and S. Iwadare, *J. Antibiot.*, 1986, **39**, 304–305.
- 70 H. C. Potgieter, N. M. J. Vermeulen and D. J. J. Potgieter, *Phytochemistry*, 1977, **16**, 1757–1759.
- 71 P. Brzović, E. L. Holbrook, R. C. Greene and M. F. Dunn, *Biochemistry*, 1990, **29**, 442–451.
- 72 D. V. Kuklev, A. J. Domb and V. M. Dembitsky, *Phytomedicine*, 2013, **20**, 1145–1159.
- 73 K. Sakai, T. Hirose, M. Iwatsuki, T. Chinen, T. Kimura, T. Suga, K. Nonaka, T. Nakashima, T. Sunazuka, T. Usui, Y. Asami, S. Ōmura and K. Shiomi, *J. Nat. Prod.*, 2018, **81**, 1604–1609.
- 74 P. Lan, L. E. White, E. S. Taher, P. E. Guest, M. G. Banwell and A. C. Willis, *J. Nat. Prod.*, 2015, **78**, 1963–1968.
- 75 J. Li, S. Park, R. L. Miller and D. Lee, *Org. Lett.*, 2009, **11**, 571–574.
- 76 H. Zhao, G. D. Chen, J. Zou, R. R. He, S. Y. Qin, D. Hu, G. Q. Li, L. D. Guo, X. S. Yao and H. Gao, *Org. Lett.*, 2017, **19**, 38–41.
- 77 Y. Pan, L. Liu, F. Guan, E. Li, J. Jin, J. Li, Y. Che and G. Liu, *ACS Chem. Biol.*, 2018, **13**, 703–711.
- 78 D. O'Hagan, C. Schaffrath, S. L. Cobb, J. T. G. Hamilton and C. D. Murphy, *Nature*, 2002, **416**, 279.
- 79 V. Agarwal, Z. D. Miles, J. M. Winter, A. S. Eustaquio, A. A. El Gamal and B. S. Moore, *Chem. Rev.*, 2017, **117**, 5619–5674.
- 80 Y. Sugai, Y. Katsuyama and Y. Ohnishi, *Nat. Chem. Biol.*, 2016, **12**, 73–75.
- 81 F. Amblard, J. H. Cho and R. F. Schinazi, *Chem. Rev.*, 2009, **109**, 4207–4220.
- 82 J. Lehmann, M. H. Wright and S. A. Sieber, *Chemistry*, 2016, **22**, 4666–4678.
- 83 E. S. Hems, B. A. Wagstaff and G. Saalbach, *Chem. Commun.*, 2018, **54**, 12234–12237.
- 84 I. Koryakina, C. Kasey, J. B. McArthur, A. N. Lowell, J. A. Chemler, S. Li, D. A. Hansen, D. H. Sherman and G. J. Williams, *ACS Chem. Biol.*, 2017, **12**, 114–123.
- 85 X. Zhu and W. Zhang, *Front. Chem.*, 2015, **3**, 11.
- 86 X. Zhu, P. Shieh, M. Su, C. R. Bertozzi and W. Zhang, *Chem. Commun.*, 2016, **52**, 11239–11242.



- 87 M. Sandy, Z. Rui, J. Gallagher and W. Zhang, *ACS Chem. Biol.*, 2012, **7**, 1956–1961.
- 88 Y. Yan, J. Chen, L. Zhang, Q. Zheng, Y. Han, H. Zhang, D. Zhang, T. Awakawa, I. Abe and W. Liu, *Angew. Chem., Int. Ed.*, 2013, **52**, 12308–12312.
- 89 W. B. Porterfield, N. Poenateetai and W. Zhang, *iScience*, 2020, **23**, 100938.
- 90 C. Bihlmaier, E. Welle, C. Hofmann, K. Welzel, A. Vente, E. Breitling, M. Muller, S. Glaser and A. Bechthold, *Antimicrob. Agents Chemother.*, 2006, **50**, 2113–2121.
- 91 B. J. Rawlings, *Nat. Prod. Rep.*, 2001, **18**, 190–227.
- 92 S. Yuzawa, K. Deng, G. Wang, E. E. Baidoo, T. R. Northen, P. D. Adams, L. Katz and J. D. Keasling, *ACS Synth. Biol.*, 2017, **6**, 139–147.

